Volkan Solmaz, Elmas Pekdaş Genç, Dürdane Aksoy, Betül Çevik, Semiha Gülsüm Kurt, İsmail Benli

Parkinson hastalığında nötrofil/lenfosit oranları, C reaktif protein ve sedimantasyon hızları

Amaç: Parkinson hastalığı (PH) olan kişilerin kanlarında nötrofil/lenfosit (N/L) oranları, sedimentasyon hızı (ESR), C-reaktif protein (CRP) düzeylerini sağlıklı kişilerle karşılaştırarak değerlendirmeyi amaçladık. Gereç ve Yöntem: Çalışmamıza benzer yaş ve cinsiyetten 101 PH ve 60 sağlıklı gönüllü katılımcı aldık. Hastaların sosyodemografik verileri, hastalık süreleri, kullandığı ilaçlar ve Hoehn-Yahr evreleri kaydedildi. Tam bir nörolojik muayeneden sonar hastaların kan örnekleri alınarak, nötrofil ve lenfosit sayılar, CRP ve ESR düzeyleri incelendi.Bulgular:N/L oranları ve CRP düzeyleri sağlıklı kişilerle kıyaslandığında PH olanlarda istatistiksel olarak anlamlı şekilde yüksek olduğu görüldü, ayrıca N/L oranları ile CRP düzeyleri arasında istatistiksel olarak anlamlı ancak zayıf bir korelasyonun olduğu tespit edildi. Benzer şekilde CRP düzeyleri ile N/L oranları ve Hoehn-Yahr evreleri arasında istatistiksel olarak anlamlı ancak zayıf bir korelasyonun olduğu görüldü. Hasta grubunda N/L oranları ayrı ayrı CRP ve ESR ile korele edildiğinde sadece N/L ile CRP arasında istatistiksel olark anlamlı zayıf bir korelasyon vardı.Sonuç: Çalışmamızda periferik inflamasyonun çok iyi birer göstergeleri olan N/L oranları ve CRP düzeylerinin PH’ larında anlamlı olarak daha yüksek olduğunu tespit ettik. Bulgularımız bu markerların PH için tanısal değeri olabilceğini düşündürmektedir

Anahtar Kelimeler:

idiopatik Parkinson hastalığı, nötrofil-lenfosit oranı, C-RP, periferik inflamasyon

Serum neutrophil-lymphocyte ratios, C-reactive protein and sedimentation levels in Parkinson's disease

Purpose: We aimed to investigate the systemic inflammation status by analyzing the Neutrophil/Lymphocyte (N/L) ratio, Erythrocyte Sedimentation Rate (ESR), and C - reactive protein (CRP) in patients with Parkinson’s disease (PD).Materials and Methods: 101 PD patients, and 60 healthy subjects of similar age and gender were include in this study. The demographic data and duration of the disease, the drugs, duration of usage of Parkinson drugs, Hoehn-Yahr stage were noted. After full neurological examination blood samples are collected and neutrophil, lymphocyte counts, high sensitive CRP, ESR levels are detected.Results: The N/L ratio and the CRP levels were statistically higher in Parkinson’s group. There was a statistically significant but weak positive correlation between the CRP levels and the N/L ratio with the disease duration. Similarly, there was a statistically significant but weak positive correlation between the CRP levels and the N/L ratios with Hoehn-Yahr stages. When the N/L rates of the Parkinson's patients were correlated with the CRP and the ESR levels separately, it was observed that there was a weak but statistically significant correlation between the CRP and the N/L ratioConclusion: N/L ratio, and CRP levels, which are very important indicators of peripheral inflammation, was higher in PD. Our findings suggest that these biochemical markers may have a predictive value for the diagnosis of PD.

Keywords:

Idiopathic Parkinson disease, neutrophil-lymphocyte ratio, C-RP,

PDF

___

1. Evlice AT, Aslan K, Bozdemir H, Demirkiran M, Unal I, Bicakcı S. Nörolojik hastalıklarda özürlülük. Cukurova Medical Journal. 2014;39:566-71.
2. Fahn S PS. Parkinsonism. In Merritt’s Textbook of Neurology, 10th edition (Ed LP Rowland). Philadelphia, Lippincott Williams Wilkins, 2000
3. Watts RL, Koller WC. Movement Disorders: Neurologic Principles and Practice, 2nd edition. New York, McGraws Hill, 1997. 4. Adams RD VM, Ropper AH. Principles of Neurology, 6th Ed. New York, NY, McGraw-Hill. 1997.
5. Li JY, Ma SS, Huang QY, Li MT. The function of neuroinflammation in Parkinson disease. Sheng Li Ke Xue Jin Zhan. 2015;46:175-9.
6. Lopez Gonzalez I, Garcia-Esparcia P, Llorens F, Ferrer I. Genetic and transcriptomic profiles of inflammation in neurodegenerative diseases: Alzheimer, Parkinson, Creutzfeldt-Jakob and Tauopathies. Int J Mol Sci. 2016;17:86-7.
7. Erbas O, Cinar BP, Solmaz V, Cavusoglu T, Ates U. The neuroprotective effect of erythropoietin on experimental Parkinson model in rats. Neuropeptides. 2015;49:1-5.
8. Blesa J, Phani S, Jackson-Lewis V, Przedborski S. Classic and new animal models of Parkinson's disease. J Biomed Biotechnol. 2012;2012:845618.
9. Devos D, Lebouvier T, Lardeux B, Biraud M, Rouaud T, Pouclet H et al. Colonic inflammation in Parkinson's disease. Neurobiol Dis. 2013;50:42-8.
10. Villaran RF, Espinosa-Oliva AM, Sarmiento M, De Pablos RM, Arguelles S, Delgado-Cortes MJ et al. Ulcerative colitis exacerbates lipopolysaccharide-induced damage to the nigral dopaminergic system: potential risk factor in Parkinson`s disease. J Neurochem. 2010;114:1687-700.
11. Shannon KM, Keshavarzian A, Mutlu E, Dodiya HB, Daian D, Jaglin JA et al. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord. 2012;27:709-15.
12. Gustot A, Gallea JI, Sarroukh R, Celej MS, Ruysschaert JM, Raussens V. Amyloid fibrils are the molecular trigger of inflammation in Parkinson's disease. Biochem J. 2015;471:323-33
13. Lawand NB, Saade NE, El-Agnaf OM, Safieh-Garabedian B. Targeting alpha-synuclein as a therapeutic strategy for Parkinson's disease. Expert Opin Ther Targets. 2015;19:1351-60.
14. Akil E, Bulut A, Kaplan I, Ozdemir HH, Arslan D, Aluclu MU. The increase of carcinoembryonic antigen (CEA), high-sensitivity C-reactive protein, and neutrophil/lymphocyte ratio in Parkinson's disease. Neurol Sci. 2015;36:423-8.
15. Rembach A, Watt AD, Wilson WJ, Rainey-Smith S, Ellis KA, Rowe CC et al. An increased neutrophil-lymphocyte ratio in Alzheimer's disease is a function of age and is weakly correlated with neocortical amyloid accumulation. J Neuroimmunol. 2014;273:65-71.
16. Kuyumcu ME, Yesil Y, Ozturk ZA, Kizilarslanoglu C, Etgul S, Halil M et al. The evaluation of neutrophil-lymphocyte ratio in Alzheimer's disease. Dement Geriatr Cogn Disord. 2012;34:69-74.
17. Koklu E, Yuksel IO, Arslan S, Bayar N, Cagirci G, Gencer ES et al. Is elevated neutrophil-to-lymphocyte ratio a predictor of stroke in patients with intermediate carotid artery stenosis? J Stroke Cerebrovasc Dis. 2016;25:578-84.
18. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181-4.
19. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427-42.
20. de Farias CC, Maes M, Bonifacio KL, Bortolasci CC, de Souza Nogueira A, Brinholi FF et al. Highly specific changes in antioxidant levels and lipid peroxidation in Parkinson's disease and its progression: Disease and staging biomarkers and new drug targets. Neurosci Lett. 2016;617:66-71.
21. Umemura A, Oeda T, Yamamoto K, Tomita S, Kohsaka M, Park K et al. Baseline plasma c-reactive protein concentrations and motor prognosis in Parkinson disease. PloS One. 2015;10:0136722.
22. Sawada H, Oeda T, Umemura A, Tomita S, Kohsaka M, Park K et al. Baseline c-reactive protein levels and life prognosis in Parkinson Disease. PloS one. 2015;10:0134118.
23. Song IU, Cho HJ, Kim JS, Park IS, Lee KS. Serum hs-CRP levels are increased in de Novo Parkinson's disease independently from age of onset. Eur Neurol. 2014;72:285-89.
24. Hassin-Baer S, Cohen OS, Vakil E, Molshazki N, Sela BA, Nitsan Z et al. Is C-reactive protein level a marker of advanced motor and neuropsychiatric complications in Parkinson's disease? J Neural Transm (Vienna). 2011;118:539-43